<DOC>
	<DOCNO>NCT01343173</DOCNO>
	<brief_summary>Background : Complete molecular remission imatinib , therapeutic interruption possible patient complete remission prove different trial . Purpose : Stopping imatinib patient chronic myeloid leukemia complete molecular remission two follow year . The objective study determine rate patient without molecular relapse rate molecular relapse , determine seek clinical biological CML-related factor predictive molecular relapse imatinib discontinuation . These objective require increase number study patient enrol accurate statistical consideration . It allow predict patient propose discontinuation without risk molecular relapse select patient need continue reinforce treatment achieve complete long term eradication disease .</brief_summary>
	<brief_title>Multicenter Trial Estimating Persistence Molecular Remission Chronic Myeloid Leukaemia Long Term After Stopping Imatinib</brief_title>
	<detailed_description>The gold standard treatment chronic myeloid leukaemia ( CML ) Imatinib , first tyrosine inhibitor ( TKI ) BCR-ABL . Imatinib specifically target BCR-ABL tyrosine kinase encode BCR-ABL fusion gene , molecular hallmark CML . Regular monitoring BCR-ABL transcript level quantitative RT-PCR key importance assessment treatment response imatinib . Over time , increase proportion imatinib-treated patient obtain complete molecular response ( CMR ) , define undetectable molecular residual disease . In previous study , STIM trial ( PHRC 2006 , stop Imatinib ) , 100 patient include . The preliminary analysis among 69 patient median follow 21 month show probability maintain CMR 12 month 45 % . Our goal actually include 200 patient let STIM open 3 year way determine predictive factor molecular relapse Discontinuation treatment propose check selection criterion sign informed consent . The assessment BCR-ABL peripheral blood quantitative RT-PCR perform every month first year every two month second year every three month 3 year . The molecular relapse imatinib discontinuation define positive PCR BCR-ABL two time use RTQ-PCR increase transcript two follow assessment value &gt; 0.1 % i.e . lose MMR . In case molecular relapse recommend re-challenge imatinib treatment . According experience 50 patient well document challenge treatment sensitive . The treatment molecular relapse second generation tyrosine kinase inhibitor ( dasatinib nilotinib ) possible current trial . It important French patient include national trial avoid discontinuation without evaluation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>18 year old . Chronic myeloid leukaemia chronic accelerate phase treatment imatinib least 3 year . Complete molecular remission treatment imatinib least 2 year . HIV serology negative absence chronic hepatitis B C. Molecular monitoring accord international recommendation begin study For woman old enough procreate , method effective contraception All patient must inform investigational nature study must sign give write informed consent . Under 18 year old . Pregnant inclusion 's time . Hospitalized patient without consent . Adults law protection without ability assent . Previous plan allogeneic stem cell transplantation . HIV serology positive chronic hepatitis B C. Interfering treatment ( corticosteroid , immunosuppressor , chemotherapy , radiotherapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Adult Chronic</keyword>
	<keyword>Myeloid</keyword>
</DOC>